NorthStar Medical Radioisotopes has received a custom-built IBA Rhodotron TT 300-HR electron beam accelerator to its new Ac-225 Production facility, the organization announced recently.

According to a release, the accelerator technology will produce high purity, non-carrier-added Ac-225 that is free of long-lived radioactive byproducts associated with other production methods, which pose regulatory and waste management challenges for hospitals, health systems and other healthcare instituions.

“Delivery of this electron beam accelerator brings NorthStar Medical Radioisotopes a step closer to commercial production of Ac-225 and marks a tremendous milestone event for NorthStar, nuclear medicine and patient health,” NorthStar Medical Radioisotopes CEO Stephen Merrick said in a statement. “We all (partners and stakeholders) share a vision to accelerate the future of patient health by providing innovative solutions to ensure robust, reliable access to radioisotopes that can make a positive difference in healthcare for people around the world.”

Ac-225 can be used in clinical studies that use targeted radiopharmaceutical therapy (RPT).